Omeros Corp (OMER) company profile
Close on Nov 17, 2026Market cap $1.01BP/E –Yield –
About Omeros
Pharmaceutical Preparations, SIC 2834
Omeros Corporation is a commercial-stage biopharmaceutical company that discovers and develops protein and small-molecule therapeutics for complement-mediated diseases, cancers, and addictive disorders. Its approved commercial product is YARTEMLEA, a MASP-2 inhibitor for stem cell transplant-associated thrombotic microangiopathy. Its development pipeline includes complement inhibitors, PDE7 inhibitors for addiction and movement disorders, oncology candidates for leukemia, and infectious disease therapies. The company's customers are stem cell transplant centers, hospitals, and specialized medical teams treating adult and pediatric patients.
Commercial distribution and clinical operations focus primarily on the United States, alongside regulatory review across European Union and European Economic Area member countries. Within the United States, commercial outreach covers 175 stem cell transplant centers, prioritizing the top 80 facilities that conduct roughly 80 percent of procedures. Outside the domestic market, Omeros explores regional and international partnerships. Contract manufacturers perform commercial drug manufacturing, sterile vial filling, and packaging. The text does not disclose the company's headquarters location.
Summary of the business section of Omeros's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Omeros Corp
- Founded
- 1994
- Headquarters
- Seattle, WA
- Address
- 201 Elliott Avenue West 98119
- Phone
- (206) 676-5000
- Website
- www.omeros.com
- Employees
- 175, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Washington
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Seattle, Washington
Stock & identifiers
- Ticker
- OMER
- Exchange
- Nasdaq
- IPO date
- Oct 8, 2009
- Shares outstanding
- 72M, Aug 7, 2026
- Public float
- $172.38M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1285819
- CUSIP
- 682143102
- ISIN
- US6821431029
- FIGI
- BBG000JLP4B4
- Share class FIGI
- BBG001SPJH21
- LEI
- 549300CJWLXX2MXVVV71
- EIN
- 91-1663741
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gregory A. Demopulos MD | Chairman, CEO & President, Director | 2,250,931 |
| David J. Borges | VP, Finance & CAO | 0 |
| Peter B. Cancelmo | VP, General Counsel | 25,200 |
| Arnold C. Hanish | Director | 14,900 |
| Thomas J. Cable | Director | 50,067 |
| Joseph L. Schocken | Director | 528,082 |
| Peter A. Demopulos MD | Director | 372,898 |
| Leroy E. MD Hood PhD | Director | 74,390 |
| Rajiv Shah | Director | – |
| Thomas F. Bumol | Director | 10,000 |
| Diana T. Perkinson | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.18M | $17.58M | $803.49K | $760 | – |
| FY2024 | $3.76M | $12.37M | $743.62K | $437 | – |
| FY2023 | $7.69M | $8.69M | $853.30K | $145 | – |
| FY2022 | $3.73M | $1.33M | $756.39K | $35 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board | $972.53K | $972.53K | $2.21M | $24.98K | $4.18M | +11% |
| David J. Borges Vice President, Finance, Chief Accounting Officer and Treasurer | $325.60K | $113.75K | $242.49K | $4.43K | $686.27K | +9% |
| Peter B. Cancelmo, J.D. Vice President, General Counsel and Secretary | $489.48K | $171.32K | $255.26K | $4.65K | $920.70K | +2% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 8, 2009
- Offer price
- $10.00
- Securities offered
- 6,820,000
- Gross proceeds
- $68.20M
- Exchange
- Nasdaq
- First trading day
- Oct 8, 2009
- First-day close
- $8.73-12.7%
- Lock-up ends (est.)
- Apr 6, 2010
“Per Share Total Public offering price $ 10.00 $ 68,200,000 Underwriting discounts and commissions(1) $ 0.70 $ 4,774,000 Proceeds, before expenses, to Omeros Corporation $ 9.30 $ 63,426,000 We have granted the underwriters the right to purchase up to 1,023,000 additional shares of common stock to cover over-allotmen”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 175 full-time employees, 116 of whom are in research and development, 15 of whom are in sales and marketing and 44 of whom are in finance, legal, business development and administration.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 1, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 30, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 23, 2010 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 8, 2009 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 30, 2009 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?